- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03805178
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
Lung Transplant Plasmapheresis (PLEX)/Belatacept/Carfilzomib Protocol for Treatment of Antibody Mediated Rejection (AMR) and Desensitization
Study Overview
Status
Intervention / Treatment
Detailed Description
Antibody mediated rejection (AMR) post transplant contributes to poor long term outcomes after lung transplantation. Additionally, high antibodies detected pre transplant in candidates limit donor availability for lung transplant. Multimodal therapies with rituximab, intravenous immunoglobulin, plasmapheresis and proteasome inhibitors have not significantly altered the antibodies in these patients. Belatacept targets the T and B cell interaction such that it represents a novel therapeutic strategy. This proposal would include belatacept in a multi-therapy regimen.
This is an open label study with two patient cohorts for safety and efficacy of belatacept in a multi-modal protocol. The two patient cohorts are an AMR post-transplant cohort and pre-transplant desensitization cohort. A total of 10 patients will be enrolled.The primary objection is drug tolerability and secondary objectives are antibody measurements and allograft function.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion criteria for the AMR post-transplant cohort
- Positive DSAs and allograft dysfunction defined by changes in pulmonary physiology, gas exchange, radiological features or deteriorating functional performance that is highly suspicious for AMR
- Recipient is Epstein-Barr virus positive (EBV+) by serology
- Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure
Inclusion criteria for the pre-transplant desensitization cohort
- Elevated HLA antibodies (defined as MFI >1000) such that the calculated panel reactive antibodies are >60%
- At least 2 HLA antibodies with Mean Fluorescent Intensity (MFI) <10,000 and at least 2 HLA antibodies with MFI <5,000 on undiluted serum that do not demonstrate an increase in MFI with dilution at 1:16 (no evidence of a prozone effect).
- EBV+ by serology
- Clinically stable defined by not on invasive mechanical ventilation, extracorporeal membrane oxygenation support or other invasive life support requiring ICU level of care
- Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure
Exclusion criteria for both AMR post-transplant cohort and pre-transplant cohort
- Active systemic infection
- Allergy to carfilzomib or belatacept
- Known malignancy in the previous 2 years except for non-melanomatous skin cancer
- Pregnancy
- Inability to commit to complete treatment protocol at Duke as all procedures must be completed at Duke
- Prisoners or those who are compulsory detained
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rejection post-transplant
Treatment with Belatacept and Carfilzomib for subjects who show evidence of antibody-mediated rejection (AMR) following lung transplantation.
|
Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase. No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen.
Other Names:
20mg/m2 Plasmapheresis
Other Names:
|
Experimental: Pre-transplant desensitization
Treatment with Belatacept and Carfilzomib for subjects with elevated human leukocyte antigen (HLA) antibodies prior to lung transplantation.
|
Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase. No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen.
Other Names:
20mg/m2 Plasmapheresis
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of drug side effects
Time Frame: Within 28 days of last administration of study drugs
|
Drug tolerability with respect to freedom from drug side effects measured using descriptive statistics
|
Within 28 days of last administration of study drugs
|
Occurrence of infection
Time Frame: Within 28 days of last administration of study drugs
|
Drug tolerability with respect to freedom from infection measured using descriptive statistics
|
Within 28 days of last administration of study drugs
|
Occurrence of malignancy
Time Frame: Within 28 days of last administration of study drugs
|
Drug tolerability with respect to freedom from malignancy measured using descriptive statistics
|
Within 28 days of last administration of study drugs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects in the AMR cohort with resolution of at least one donor specific human leukocyte antigen (HLA) antibody (DSA)
Time Frame: Within 4 weeks of completion of treatment
|
Descriptive statistical report of number of subjects who had resolution of at least one DSA measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody.
|
Within 4 weeks of completion of treatment
|
Number of subjects in the AMR cohort with improvement or stabilization of lung function as measured by spirometry data
Time Frame: Within 4 weeks of completion of treatment
|
Pulmonary function (spirometry) data will track forced vital capacity (FVC), forced expiratory volume (FEV1) and forced expiratory flow (FEF) 25-75%.
Changes in spirometry will be reported as stabilized, improved or worsened based on comparison of baseline spirometry values obtained prior to treatment plan with serial spirometric testing performed at specified intervals in treatment plan.
|
Within 4 weeks of completion of treatment
|
Number of subjects in the AMR cohort with improvement in oxygenation as measured by Liters/min oxygen at rest
Time Frame: Within 4 weeks of completion of treatment
|
Gas exchange will be reported as no change, worsening exchange or improving exchange based on comparison of resting oxygen requirements before and following treatment plan.
|
Within 4 weeks of completion of treatment
|
Number of subjects in the AMR cohort with decrease in DSA by one log
Time Frame: Within 4 weeks of completion of treatment
|
Descriptive statistical report of number of subjects who had a decrease in DSA measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody.
|
Within 4 weeks of completion of treatment
|
Number of subjects in the AMR cohort with elimination of DSA at 1:16 dilution
Time Frame: Within 4 weeks of completion of treatment
|
Descriptive statistical report of number of subjects who had elimination of DSA at 1:16 dilution measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody.
|
Within 4 weeks of completion of treatment
|
Number of subjects in the transplant desensitization cohort with decrease in non-DSA HLA antibodies by one log
Time Frame: Within 4 weeks of completion of treatment
|
Descriptive statistical report of number of subjects who had a decrease in non-DSA HLA antibodies measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody.
|
Within 4 weeks of completion of treatment
|
Number of subjects in the transplant desensitization cohort with elimination of non-DSA HLA antibodies at 1:16 dilution
Time Frame: Within 4 weeks of completion of treatment
|
Descriptive statistical report of number of subjects who had elimination of non-DSA HLA antibodies at 1:16 dilution measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody.
|
Within 4 weeks of completion of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Laurie Snyder, Duke University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00101289
- IM103-407 (Other Grant/Funding Number: Bristol-Myers Squibb)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Transplant Rejection
-
Stanford UniversityKaiser Foundation Research InstituteCompletedLung Transplant Rejection | Cardiac Transplant RejectionUnited States
-
Hopital FochRecruitingLung Transplant Rejection | Lung Transplant Failure | Lung Transplant; Complications | Lung Transplant Failure and RejectionFrance
-
University of ZurichRecruitingLung Transplant Rejection | Lung Transplant Failure and RejectionSwitzerland
-
Medical University of ViennaRecruitingLung Transplant Rejection | Antibody-mediated RejectionAustria
-
Washington University School of MedicineBristol-Myers Squibb; National Heart, Lung, and Blood Institute (NHLBI)CompletedLung Transplant Rejection | Antibody-mediated RejectionUnited States
-
Xemed LLCChildren's Hospital of Philadelphia; University of PennsylvaniaRecruiting
-
University of AlbertaRecruitingLung Transplant RejectionCanada, United States, Australia, Austria, Czechia, Poland
-
Paris Translational Research Center for Organ TransplantationHopital FochCompleted
-
John F. McDyer, MDCompletedLung Transplant RejectionUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownLung Transplant RejectionSpain
Clinical Trials on Belatacept
-
Bristol-Myers SquibbCompletedRenal TransplantationUnited States
-
Guizhou Provincial People's HospitalActive, not recruiting
-
Bristol-Myers SquibbCompletedKidney Transplantation | Chronic Kidney FailureUnited States, Argentina, Australia, Germany, Italy, South Africa, Spain, Brazil, Mexico, Belgium, France, Hungary, Switzerland, India, Canada, Austria, Czech Republic, Poland, Israel, Sweden, Turkey
-
Methodist Health SystemActive, not recruitingUse of Belatacept in Kidney Transplant PatientsUnited States
-
Bristol-Myers SquibbCompletedRenal TransplantationUnited States, Argentina, Germany, Italy, Chile, Spain, Brazil, Sweden, Belgium, France, Hungary, Australia, South Africa, Austria, Canada, United Kingdom, Poland, Czechia, Norway
-
Bristol-Myers SquibbCompletedHealthy VolunteersUnited States
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States, Netherlands, Belgium, Canada, Germany, France, Ireland, Switzerland, United Kingdom
-
Bristol-Myers SquibbTerminatedImmunosuppression in Solid Organ TransplantFrance, Germany, Italy, United States, Austria, Canada, Spain, Argentina, Brazil
-
University of MarylandBristol-Myers SquibbCompletedEnd-Stage Renal DiseaseUnited States
-
Ain Shams UniversityRecruiting